5-BPDi (Indanyl-α-PHP) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug, first reported in 2015.[1][2]
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H27NO |
| Molar mass | 285.431 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ Błażewicz A, Bednarek E, Popławska M, Olech N, Sitkowski J, Kozerski L (July 2019). "Identification and structural characterization of synthetic cathinones: N-propylcathinone, 2,4-dimethylmethcathinone, 2,4-dimethylethcathinone, 2,4-dimethyl-α-pyrrolidinopropiophenone, 4-bromo-α-pyrrolidinopropiophenone, 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one and 2,4-dimethylisocathinone". Forensic Toxicology. 37 (2): 288–307. doi:10.1007/s11419-018-00463-w.
- ^ Pulver B, Riedel J, Westphal F, Luhn S, Schönberger T, Schäper J, et al. (January 2023). "A new synthetic cathinone: 3,4-EtPV or 3,4-Pr-PipVP? An unsuccessful attempt to circumvent the German legislation on new psychoactive substances". Drug Testing and Analysis. 15 (1): 84–96. doi:10.1002/dta.3371. PMID 36136085.